ConforMIS Inc Form 10-Q November 09, 2015
Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2015
OR
O TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGI ACT OF 1934
For the transition period from to

Edgar Filing: ConforMIS Inc - Form 10-Q Commission file number: 001-37474 ConforMIS, Inc. (Exact name of registrant as specified in its charter) **Delaware** 56-2463152 (I.R.S. Employer (State or other jurisdiction of incorporation or organization) Identification Number) 28 Crosby Drive Bedford, MA 01730 (Address of principal executive offices) (Zip Code) (781) 345-9001 (Registrant s telephone number, including area code) (Former name, former address and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data

File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

for such shorter period that the registrant was required to submit and post such files). Yes x No o

Large accelerated filer

0

0

Accelerated filer

Non-accelerated filer x (Do not check if a smaller reporting company) Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of October 30, 2015 there were 40,712,347 shares of Common Stock, \$0.00001 par value per share, outstanding.

Table of Contents

ConforMIS, Inc.

INDEX

	Page
PART I FINANCIAL INFORMATION	
<u>Item 1. Financial Statements (interim periods unaudited)</u>	3
Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014	3
Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014	2
Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2015 and 2014	4
Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014	(
Notes to Consolidated Financial Statements	7
Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations	30
Item 3. Quantitative and Qualitative Disclosures About Market Risk	41
Item 4. Controls and Procedures	42
PART II OTHER INFORMATION	43
Item 1. Legal Proceedings	43
Item 1A. Risk Factors	43
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	47
Item 6. Exhibits	48
<u>Signatures</u>	49
2	

PART I FINANCIAL INFORMATION

Item 1. Financial Statements.

CONFORMIS, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(in thousands, except share and per share data)

	ber 30, 2015 audited)	December 31, 2014
Assets		
Current Assets		
Cash and cash equivalents	\$ 139,202 \$	37,900
Accounts receivable, net	8,260	9,119
Inventories	10,664	7,691
Prepaid expenses and other current assets	2,124	1,158
Total current assets	160,250	55,868
Property and equipment, net	10,655	8,696
Other Assets		
Restricted cash	720	4,438
Intangible assets, net	1,057	1,243
Goodwill	753	753
Other long-term assets	283	280
Total assets	\$ 173,718 \$	71,278
Liabilities and stockholder s equity		
Current liabilities		
Accounts payable	\$ 5,849 \$	3,618
Accrued expenses	6,953	6,942
Deferred revenue	305	
Current portion of long-term debt	289	272
Total current liabilities	13,396	10,832
Other long-term liabilities	240	271
Deferred revenue	4,701	
Long-term debt	258	10,348
Total liabilities	18,595	21,451
Commitments and contingencies		
Stockholders equity		
Convertible preferred stock, \$0,00001 par value:		

Convertible preferred stock, \$0.00001 par value:

Authorized: Zero and 53,496,241 shares authorized at September 30, 2015 and December 31, 2014, respectively, zero and 50,985,652 shares issued and outstanding September 30, 2015 and December 31, 2014, respectively; (aggregate liquidation value of \$0 and \$352,626 at September 30, 2015 and December 31, 2014, respectively)

Preferred stock, \$0.00001 par value:

Authorized: 5,000,000 and zero shares authorized at September 30, 2015 and December 31, 2014, respectively; no shares issued and outstanding as of

September 30, 2015 and December 31, 2014

Common stock, \$0.00001 par value:

Authorized: 200,000,000 and 80,000,000 shares authorized at September 30, 2015 and December 31, 2014, respectively; 40,709,155 and 4,286,164 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively

Additional paid-in capital	465,818	318,420
Accumulated deficit	(310,352)	(268,096)
Accumulated other comprehensive loss	(343)	(497)
Total stockholders equity	155,123	49,827
Total liabilities and stockholders equity	\$ 173,718 \$	71,278

The accompanying notes are an integral part of these consolidated financial statements.

CONFORMIS, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

(unaudited)

(in thousands, except share and per share data)

		Three Months Ended September 30,		Nine Months Ended September 30,			
		2015		2014	2015	_	2014
Revenue							
Product	\$	13,490	\$	12,002 \$	43,953	\$	33,975
Royalty		404			3,863		
Total revenue		13,894		12,002	47,816		33,975
Cost of revenue		10,340		7,351	30,392		21,961
Gross profit		3,554		4,651	17,424		12,014
Operating expenses							
Sales and marketing		10.225		7.083	29,563		22,541
Research and development		3,885		3,969	12,218		11,163
General and administrative		5,656		3.927	16,790		11,775
Total operating expenses		19,766		14,979	58,571		45,479
Loss from operations		(16,212)		(10,328)	(41,147)		(33,465)
Other income and expenses							
Interest income		24		30	92		80
Interest expense		(911)		(89)	(1,380)		(178)
Other income (expense)		(911)		(67)	208		(176)
Total other expenses		(887)		(59)	(1,080)		(98)
Loss before income taxes		(17,099)		(10,387)	(42,227)		(33,563)
Income tax provision		8		9	29		29
Net loss	\$	(17,107)	\$	(10,396) \$	(42,256)	\$	(33,592)
Net loss per share - basic and diluted	\$	(0.45)	\$	(2.44) \$	(2.69)	\$	(7.95)
The 1000 per office outle did did did	Ψ	(0.13)	Ψ	(2.11) ψ	(2.07)	Ψ	(1.55)
Weighted average common shares outstanding -							
basic and diluted		37,933,069		4,267,148	15,688,686		4,224,454

The accompanying notes are an integral part of these consolidated financial statements.

CONFORMIS, INC. AND SUBSIDIARIES

Consolidated Statements of Comprehensive Loss

(unaudited)

(in thousands)

	Three Months Ended September 30,			Nine Months Ended September 30,			
		2015 2014		2015		2014	
Net loss	\$	(17,107)	\$	(10,396) \$	(42,256)	\$	(33,592)
Other comprehensive income (loss)							
Foreign currency translation adjustments		(60)		(377)	154		(543)
Comprehensive loss	\$	(17,167)	\$	(10,773) \$	(42,102)	\$	(34,135)

The accompanying notes are an integral part of these consolidated financial statements.

CONFORMIS, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

	Nine Months Ended Septer 2015			nber 30, 2014	
Cash flows from operating activities					
Net loss	\$	(42,256)	\$	(33,592)	
Adjustments to reconcile net loss to net cash used by operating activities:					
Depreciation and amortization expense		1,891		1.545	
Amortization of debt discount		135		18	
Stock-based compensation expense		2.594		1,796	
Provision for bad debts on trade receivables		171		(37)	
Disposal of long term assets		2		(4.7)	
Changes in operating assets and liabilities:					
Accounts receivable		687		(1,573)	
Inventories		(2,974)		(73)	
Prepaid expenses and other assets		(969)		(394)	
Accounts payable and accrued liabilities		2,242		281	
Deferred royalty revenue		5,009			
Other long-term liabilities		(31)		(197)	
Net cash used in operating activities		(33,499)		(32,226)	
Cash flows from investing activities:					
Acquisition of property and equipment		(3,666)		(849)	
Decrease (increase) in restricted cash		3,717		768	
Net cash (used) provided by investing activities		51		(81)	
Cash flows from financing activities:					
Net proceeds from issuance of preferred stock				21,575	
Proceeds from exercise of common stock warrant		18			
Proceeds from exercise of preferred stock warrant		4,458			
Payments on notes payable		(10,207)		(2,114)	
Net proceeds from issuance of common stock		140,327		162	
Repurchase of stock options				(52)	
Net cash provided by financing activities		134,596		19,571	
Foreign exchange effect on cash and cash equivalents		154		(543)	
(Decrease) increase in cash and cash equivalents		101,302		(13,279)	
Cash and cash equivalents, beginning of period		37,900		54,221	
Cash and cash equivalents, end of period	\$	139,202	\$	40,942	
Supplemental information:					